Cholesterol-related genes in Alzheimer's disease

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1801, Issue 8, 2010, Pages 762-773

  Wollmer, M Axel ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Beta amyloid; Genetic; Lipid; Polymorphism

Indexed keywords

ABC TRANSPORTER A1; ABC TRANSPORTER A2; ABC TRANSPORTER G1; AMYLOID BETA PROTEIN; ANGIOTENSINOGEN; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN A4; APOLIPOPROTEIN B; APOLIPOPROTEIN C1; APOLIPOPROTEIN C2; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; BREAST CANCER RESISTANCE PROTEIN; CATALASE; CAVEOLIN 1; CAVEOLIN 3; CD36 ANTIGEN; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; CLUSTERIN; CUBILIN; FATTY ACID BINDING PROTEIN; GERANYLTRANSFERASE; GLUCOSE 6 PHOSPHATASE; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; ISOPENTENYL DIPHOSPHATE DELTA ISOMERASE; LOW DENSITY LIPOPROTEIN RECEPTOR; RETINOID X RECEPTOR ALPHA; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; CHOLESTEROL METABOLISM; DNA POLYMORPHISM; GENETIC ASSOCIATION; HUMAN; PRIORITY JOURNAL; REVIEW;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; APOLIPOPROTEINS E; BRAIN; CHOLESTEROL; ENZYMES AND COENZYMES; GENES; HUMANS; LIPID METABOLISM; MODELS, BIOLOGICAL;

EID: 77953271492     PISSN: 13881981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbalip.2010.05.009     Document Type: Review

References (154)

1. Ledesma M.D., and Dotti C.G. Amyloid excess in Alzheimer's disease: what is cholesterol to be blamed for?. FEBS Lett. 580 (2006) 5525-5532
2. Solomon A., Kivipelto M., Wolozin B., Zhou J., and Whitmer R.A. Midlife serum cholesterol and increased risk of Alzheimer's and vascular dementia three decades later. Dement. Geriatr. Cogn. Disord. 28 (2009) 75-80
3. Wolozin B., Manger J., Bryant R., Cordy J., Green R.C., and McKee A. Re-assessing the relationship between cholesterol, statins and Alzheimer's disease. Acta Neurol. Scand. Suppl. 185 (2006) 63-70
4. Rockwood K. Epidemiological and clinical trials evidence about a preventive role for statins in Alzheimer's disease. Acta Neurol. Scand. Suppl. 185 (2006) 71-77
5. Kalback W., Esh C., Castaño E.M., Rahman A., Kokjohn T., Luehrs D.C., Sue L., Cisneros R., Gerber F., Richardson C., Bohrmann B., Walker D.G., Beach T.G., and Roher A.E. Atherosclerosis, vascular amyloidosis and brain hypoperfusion in the pathogenesis of sporadic Alzheimer's disease. Neurol. Res. 26 (2004) 525-539
6. Zekry D., Duyckaerts C., Moulias R., Belmin J., Geoffre C., Herrmann F., and Hauw J.J. Degenerative and vascular lesions of the brain have synergistic effects in dementia of the elderly. Acta Neuropathol. 103 (2002) 481-487
7. Strittmatter W.J., Saunders A.M., Schmechel D., Pericak-Vance M., Enghild J., Salvesen G.S., and Roses A.D. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl Acad. Sci. USA 90 (1993) 1977-1981
8. Bertram L., McQueen M.B., Mullin K., Blacker D., and Tanzi R.E. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat. Genet. 39 (2007) 17-23
9. Ho Hong S., Rhyne J., Zeller K., and Miller M. Novel ABCA1 compound variant associated with HDL cholesterol deficiency. Biochim. Biophys. Acta 1587 (2002) 60-64
10. Wollmer M.A., Streffer J.R., Lütjohann D., Tsolaki M., Iakovidou V., Hegi T., Pasch T., Jung H.H., Bergmann K., Nitsch R.M., Hock C., and Papassotiropoulos A. ABCA1 modulates CSF cholesterol levels and influences the age at onset of Alzheimer's disease. Neurobiol. Aging 24 (2003) 421-426
11. Katzov H., Chalmers K., Palmgren J., Andreasen N., Johansson B., Cairns N.J., Gatz M., Wilcock G.K., Love S., Pedersen N.L., Brookes A.J., Blennow K., Kehoe P.G., and Prince J.A. Genetic variants of ABCA1 modify Alzheimer disease risk and quantitative traits related to beta-amyloid metabolism. Hum. Mutat. 23 (2004) 358-367
12. Sundar P.D., Feingold E., Minster R.L., DeKosky S.T., and Kamboh M.I. Gender-specific association of ATP-binding cassette transporter 1 (ABCA1) polymorphisms with the risk of late-onset Alzheimer's disease. Neurobiol. Aging 28 (2006) 856-862
13. Rodríguez-Rodríguez E., Mateo I., Infante J., Llorca J., García-Gorostiaga I., Vázquez-Higuera J.L., Sánchez-Juan P., Berciano J., and Combarros O. Interaction between HMGCR and ABCA1 cholesterol-related genes modulates Alzheimer's disease risk. Brain Res. 1280 (2009) 166-171
14. Koldamova R., Staufenbiel M., and Lefterov I. Lack of ABCA1 considerably decreases brain ApoE level and increases amyloid deposition in APP23 mice. J. Biol. Chem. 280 (2005) 43224-43235
15. Wahrle S.E., Jiang H., Parsadanian M., Hartman R.E., Bales K.R., Paul S.M., and Holtzman D.M. Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease. J. Biol. Chem. 280 (2005) 43236-43242
16. Wahrle S.E., Jiang H., Parsadanian M., Kim J., Li A., Knoten A., Jain S., Hirsch-Reinshagen V., Wellington C.L., Bales K.R., Paul S.M., and Holtzman D.M. Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J. Clin. Invest. 118 (2008) 671-682
17. Hirsch-Reinshagen V., Maia L.F., Burgess B.L., Blain J.F., Naus K.E., McIsaac S.A., Parkinson P.F., Chan J.Y., Tansley G.H., Hayden M.R., Poirier J., Van Nostrand W., and Wellington C.L. The absence of ABCA1 decreases soluble ApoE levels but does not diminish amyloid deposition in two murine models of Alzheimer disease. J. Biol. Chem. 280 (2005) 43243-43256
18. Hirsch-Reinshagen V., Chan J.Y., Wilkinson A., Tanaka T., Fan J., Ou G., Maia L.F., Singaraja R.R., Hayden M.R., and Wellington C.L. Physiologically regulated transgenic ABCA1 does not reduce amyloid burden or amyloid-beta peptide levels in vivo. J. Lipid Res. 48 (2007) 914-923
19. Wahrle S.E., Jiang H., Parsadanian M., Legleiter J., Han X., Fryer J.D., Kowalewski T., and Holtzman D.M. ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted apoE. J. Biol. Chem. 279 (2004) 40987-40993
20. Macé S., Cousin E., Ricard S., Génin E., Spanakis E., Lafargue-Soubigou C., Génin B., Fournel R., Roche S., Haussy G., Massey F., Soubigou S., Bréfort G., Benoit P., Brice A., Campion D., Hollis M., Pradier L., Benavides J., and Deleuze J.F. ABCA2 is a strong genetic risk factor for early-onset Alzheimer's disease. Neurobiol. Dis. 18 (2005) 119-125
21. Wollmer M.A., Kapaki E., Hersberger M., Muntwyler J., Brunner F., Tsolaki M., Akatsu H., Kosaka K., Michikawa M., Molyva D., Paraskevas G.P., Lütjohann D., von Eckardstein A., Hock C., Nitsch R.M., and Papassotiropoulos A. Ethnicity-dependent genetic association of ABCA2 with sporadic Alzheimer's disease. Am. J. Med. Genet. B Neuropsychiatr. Genet. 141B (2006) 534-536
22. Wollmer M.A., Sleegers K., Ingelsson M., Zekanowski C., Brouwers N., Maruszak A., Brunner F., Huynh K.D., Kilander L., Brundin R.M., Hedlund M., Giedraitis V., Glaser A., Engelborghs S., De Deyn P.P., Kapaki E., Tsolaki M., Daniilidou M., Molyva D., Paraskevas G.P., Thal D.R., Barcikowska M., Kuznicki J., Lannfelt L., Van Broeckhoven C., Nitsch R.M., Hock C., and Papassotiropoulos A. Association study of cholesterol-related genes in Alzheimer's disease. Neurogenetics 8 (2007) 179-188
23. Tansley G.H., Burgess B.L., Bryan M.T., Su Y., Hirsch-Reinshagen V., Pearce J., Chan J.Y., Wilkinson A., Evans J., Naus K.E., McIsaac S., Bromley K., Song W., Yang H.C., Wang N., DeMattos R.B., and Wellington C.L. The cholesterol transporter ABCG1 modulates the subcellular distribution and proteolytic processing of beta-amyloid precursor protein. J. Lipid Res. 48 (2007) 1022-1034
24. Kim W.S., Suryo Rahmanto A., Kamili A., Rye K.A., Guillemin G.J., Gelissen I.C., Jessup W., Hill A.F., and Garner B. Role of ABCG1 and ABCA1 in regulation of neuronal cholesterol efflux to apolipoprotein-E discs and suppression of amyloid-beta peptide generation J. Biol. Chem. 282 (2007) 2851-2861
25. Burgess B.L., Parkinson P.F., Racke M.M., Hirsch-Reinshagen V., Fan J., Wong C., Stukas S., Theroux L., Chan J.Y., Donkin J., Wilkinson A., Balik D., Christie B., Poirier J., Lütjohann D., DeMattos R.B., and Wellington C.L. ABCG1 influences the brain cholesterol biosynthetic pathway but does not affect amyloid precursor protein or apolipoprotein E metabolism in vivo. J. Lipid Res. 49 (2008) 1254-1267
26. Kanome T., Watanabe T., Nishio K., Takahashi K., Hongo S., and Miyazaki A. Angiotensin II upregulates acyl-CoA:cholesterol acyltransferase-1 via the angiotensin II Type 1 receptor in human monocyte-macrophages. Hypertens. Res. 31 (2008) 1801-1810
27. Taylor A., Ezquerra M., Bagri G., Yip A., Goumidi L., Cottel D., Easton D., Evans J.G., Xuereb J., Cairns N.J., Amouyel P., Chartier-Harlin M.C., Brayne C., and Rubinsztein D.C. Alzheimer disease is not associated with polymorphisms in the angiotensinogen and renin genes. Am. J. Med. Genet. 105 (2001) 761-764
28. Vollbach H., Heun R., Morris C.M., Edwardson J.A., McKeith I.G., Jessen F., Schulz A., Maier W., and Kölsch H. APOA1 polymorphism influences risk for early-onset nonfamiliar AD. Ann. Neurol. 58 (2005) 436-441
29. Koldamova R.P., Lefterov I.M., Lefterova M.I., and Lazo J.S. Apolipoprotein A-I directly interacts with amyloid precursor protein and inhibits A beta aggregation and toxicity. Biochemistry 40 (2001) 3553-3560
30. Fagan A.M., Christopher E., Taylor J.W., Parsadanian M., Spinner M., Watson M., Fryer J.D., Wahrle S., Bales K.R., Paul S.M., and Holtzman D.M. ApoAI deficiency results in marked reductions in plasma cholesterol but no alterations in amyloid-beta pathology in a mouse model of Alzheimer's disease-like cerebral amyloidosis. Am. J. Pathol. 165 (2004) 1413-1422
31. Császár A., Kálmán J., Szalai C., Janka Z., and Romics L. Association of the apolipoprotein A-IV codon 360 mutation in patients with Alzheimer's disease. Neurosci. Lett. 230 (1997) 151-154
32. Chartier-Harlin M.C., Parfitt M., Legrain S., Pérez-Tur J., Brousseau T., Evans A., Berr C., Vidal O., Roques P., and Gourlet V. Apolipoprotein E, epsilon 4 allele as a major risk factor for sporadic early and late-onset forms of Alzheimer's disease: analysis of the 19q13.2 chromosomal region. Hum. Mol. Genet. 3 (1994) 569-574
33. Schellenberg G.D., Deeb S.S., Boehnke M., Bryant E.M., Martin G.M., Lampe T.H., and Bird T.D. Association of an apolipoprotein CII allele with familial dementia of the Alzheimer type. J. Neurogenet. 4 (1987) 97-108
34. Sun Y., Shi J., Zhang S., Tang M., Han H., Guo Y., Ma C., Liu X., and Li T. The APOC3 SstI polymorphism is weakly associated with sporadic Alzheimer's disease in a Chinese population. Neurosci. Lett. 380 (2005) 219-222
35. Wiederkehr F., Ogilvie A., and Vonderschmitt D.J. Cerebrospinal fluid proteins studied by two-dimensional gel electrophoresis and immunoblotting technique. J. Neurochem. 49 (1987) 363-372
36. Pitas R.E., Boyles J.K., Lee S.H., Hui D., and Weisgraber K.H. Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B, E(LDL) receptors in the brain. J. Biol. Chem. 262 (1987) 14352-14360
37. Mauch D.H., Nägler K., Schumacher S., Göritz C., Müller E.C., Otto A., and Pfrieger F.W. CNS synaptogenesis promoted by glia-derived cholesterol. Science 294 (2001) 1354-1357
38. Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., Roses A.D., Haines J.L., and Pericak-Vance M.A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261 (1993) 921-923
39. Saunders A.M., Strittmatter W.J., Schmechel D., George-Hyslop P.H., Pericak-Vance M.A., Joo S.H., Rosi B.L., Gusella J.F., Crapper-MacLachlan D.R., Alberts M.J., et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 43 (1993) 1467-1472
40. Corder E.H., Saunders A.M., Risch N.J., Strittmatter W.J., Schmechel D.E., Gaskell Jr. P.C., Rimmler J.B., Locke P.A., Conneally P.M., Schmader K.E., et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat. Genet. 7 (1994) 180-184
41. Raber J., Huang Y., and Ashford J.W. ApoE genotype accounts for the vast majority of AD risk and AD pathology. Neurobiol. Aging 25 (2004) 641-650
42. Gureje O., Ogunniyi A., Baiyewu O., Price B., Unverzagt F.W., Evans R.M., Smith-Gamble V., Lane K.A., Gao S., Hall K.S., Hendrie H.C., and Murrell J.R. APOE epsilon-4 is not associated with Alzheimer's disease in elderly Nigerians. Ann. Neurol. 59 (2006) 182-185
43. Murrell J.R., Price B., Lane K.A., Baiyewu O., Gureje O., Ogunniyi A., Unverzagt F.W., Smith-Gamble V., Gao S., Hendrie H.C., and Hall K.S. Association of apolipoprotein E genotype and Alzheimer disease in African Americans. Arch. Neurol. 63 (2006) 431-434
44. Craft S., Teri L., Edland S.D., Kukull W.A., Schellenberg G., McCormick W.C., Bowen J.D., and Larson E.B. Accelerated decline in apolipoprotein E-epsilon4 homozygotes with Alzheimer's disease. Neurology 51 (1998) 149-153
45. Small G.W., Mazziotta J.C., Collins M.T., Baxter L.R., Phelps M.E., Mandelkern M.A., Kaplan A., La Rue A., Adamson C.F., Chang L., et al. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA 273 (1995) 942-947
46. Schmechel D.E., Saunders A.M., Strittmatter W.J., Crain B.J., Hulette C.M., Joo S.H., Pericak-Vance M.A., Goldgaber D., and Roses A.D. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc. Natl Acad. Sci. USA 90 (1993) 9649-9653
47. Reiman E.M., Chen K., Liu X., Bandy D., Yu M., Lee W., Ayutyanont N., Keppler J., Reeder S.A., Langbaum J.B., Alexander G.E., Klunk W.E., Mathis C.A., Price J.C., Aizenstein H.J., DeKosky S.T., and Caselli R.J. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc. Natl Acad. Sci. USA 106 (2009) 6820-6825
48. Greenberg S.M., Rebeck G.W., Vonsattel J.P.G., Gomez-Isla T., and Hyman B.T. Apolipoprotein E epsilon-4 and cerebral hemorrhage associated with amyloid angiopathy. Ann. Neurol. 38 (1995) 254-259
49. Christensen D.Z., Schneider-Axmann T., Lucassen T.A., Bayer T.A., and Wirths O. Accumulation of intraneuronal Abeta correlates with ApoE4 genotype. Acta Neuropathol. 119 (2010) 555-556
50. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.
51. Sunderland T., Mirza N., Putnam K.T., Linker G., Bhupali D., Durham R., Soares H., Kimmel L., Friedman D., Bergeson J., Csako G., Levy J.A., Bartko J.J., and Cohen R.M. Biol. Psychiatry 56 (2004) 670-676
52. Lambert J.C., Pasquier F., Cottel D., Frigard B., Amouyel P., and Chartier-Harlin M.C. A new polymorphism in the APOE promoter associated with risk of developing Alzheimer's disease. Hum. Mol. Genet. 7 (1998) 533-540
53. Michikawa M., Fan Q.W., Isobe I., and Yanagisawa K. Apolipoprotein E exhibits isoform-specific promotion of lipid efflux from astrocytes and neurons in culture. J. Neurochem. 74 (2000) 1008-1016
54. Eichner J.E., Dunn S.T., Perveen G., Thompson D.M., Stewart K.E., and Stroehla B.C. Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. Am. J. Epidemiol. 155 (2002) 487-495
55. Kim J., Basak J.M., and Holtzman D.M. The role of apolipoprotein E in Alzheimer's disease. Neuron 63 (2009) 287-303
56. Thal D.R., Larionov S., Abramowski D., Wiederhold K.H., Van Dooren T., Yamaguchi H., Haass C., Van Leuven F., Staufenbiel M., and Capetillo-Zarate E. Occurrence and co-localization of amyloid beta-protein and apolipoprotein E in perivascular drainage channels of wild-type and APP-transgenic mice. Neurobiol. Aging 28 (2007) 1221-1230
57. Deane R., Sagare A., Hamm K., Parisi M., Lane S., Finn M.B., Holtzman D.M., and Zlokovic B.V. ApoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J. Clin. Invest. 118 (2008) 4002-4013
58. Bales K.R., Verina T., Dodel R.C., Du Y., Altstiel L., Bender M., Hyslop P., Johnstone E.M., Little S.P., Cummins D.J., Piccardo P., Ghetti B., and Paul S.M. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat. Genet. 17 (1997) 263-264
59. Holtzman D.M., Bales K.R., Wu S., Bhat P., Parsadanian M., Fagan A.M., Chang L.K., Sun Y., and Paul S.M. Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer's disease. J. Clin. Invest. 103 (1999) R15-R21
60. Bales K.R., Liu F., Wu S., Lin S., Koger D., DeLong C., Hansen J.C., Sullivan P.M., and Paul S.M. Human APOE isoform-dependent effects on brain {beta}-amyloid levels in PDAPP transgenic mice. J. Neurosci. 29 (2009) 6771-6779
61. Chang S., ran Ma T., Miranda R.D., Balestra M.E., Mahley R.W., and Huang Y. Lipid- and receptor-binding regions of apolipoprotein E4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity. Proc. Natl Acad. Sci. USA 102 (2005) 18694-18699
62. Heshmati Y., Mirabzadeh A., Feizzade G., Gilanipour M., Etminan M.R., Khoram Khorshid H.R., Kamali K., Fakhri M., Moghimi N., Najmabadi H., and Ohadi M. A novel polymorphic purine complex at the 1.5 kb upstream region of the human caveolin-1 gene and risk of Alzheimer's disease; extra-short alleles and accumulated allele homozygosity. Am. J. Med. Genet. B Neuropsychiatr. Genet. 150B (2009) 248-253
63. Kang M.J., Chung Y.H., Hwang C.I., Murata M., Fujimoto T., Mook-Jung I.H., Cha C.I., and Park W.Y. Caveolin-1 upregulation in senescent neurons alters amyloid precursor protein processing. Exp. Mol. Med. 38 (2006) 126-133
64. Gaudreault S.B., Dea D., and Poirier J. Increased caveolin-1 expression in Alzheimer's disease brain. Neurobiol. Aging 25 (2004) 753-759
65. Taguchi K., Yamagata H.D., Zhong W., Kamino K., Akatsu H., Hata R., Yamamoto T., Kosaka K., Takeda M., Kondo I., and Miki T. Identification of hippocampus-related candidate genes for Alzheimer's disease. Ann. Neurol. 57 (2005) 585-588
66. Moore K.J., El Khoury J., Medeiros L.A., Terada K., Geula C., Luster A.D., and Freeman M.W. A CD36-initiated signaling cascade mediates inflammatory effects of beta-amyloid. J. Biol. Chem. 227 (2002) 47373-47379
67. Coraci I.S., Husemann J., Berman J.W., Hulette C., Dufour J.H., Campanella G.K., Luster A.D., Silverstein S.C., and El-Khoury J.B. CD36, a class B scavenger receptor, is expressed on microglia in Alzheimer's disease brains and can mediate production of reactive oxygen species in response to beta-amyloid fibrils. Am. J. Pathol. 160 (2002) 101-112
68. Bamberger M.E., Harris M.E., McDonald D.R., Husemann J., and Landreth G.E. A cell surface receptor complex for fibrillar beta-amyloid mediates microglial activation. J. Neurosci. 23 (2003) 2665-2674
69. Arias-Vásquez A., Isaacs A., Aulchenko Y.S., Hofman A., Oostra B.A., Breteler M., and van Duijn C.M. The cholesteryl ester transfer protein (CETP) gene and the risk of Alzheimer's disease. Neurogenetics 8 (2007) 189-193
70. Rodríguez E., Mateo I., Infante J., Llorca J., Berciano J., and Combarros O. Cholesteryl ester transfer protein (CETP) polymorphism modifies the Alzheimer's disease risk associated with APOE epsilon4 allele. J. Neurol. 253 (2006) 181-185
71. Sanders A.E., Wang C., Katz M., Derby C.A., Barzilai N., Ozelius L., and Lipton R.B. Association of a functional polymorphism in the cholesteryl ester transfer protein (CETP) gene with memory decline and incidence of dementia. JAMA 303 (2010) 150-158
72. Bertram L., Blacker D., Mullin K., Keeney D., Jones J., Basu S., Yhu S., McInnis M.G., Go R.C., Vekrellis K., Selkoe D.J., Saunders A.J., and Tanzi R.E. Evidence for genetic linkage of Alzheimer's disease to chromosome 10q. Science 290 (2000) 2302-2303
73. Myers A., Wavrant De-Vrieze F., Holmans P., Hamshere M., Crook R., Compton D., Marshall H., Meyer D., Shears S., Booth J., Ramic D., Knowles H., Morris J.C., Williams N., Norton N., Abraham R., Kehoe P., Williams H., Rudrasingham V., Rice F., Giles P., Tunstall N., Jones L., Lovestone S., Williams J., Owen M.J., Hardy J., and Goate A. Full genome screen for Alzheimer disease: stage II analysis. Am. J. Med. Genet. 114 (2002) 235-244
74. Mazzone T., Gump H., Diller P., and Getz G.S. Macrophage free cholesterol content regulates apolipoprotein E synthesis. J. Biol. Chem. 262 (1987) 11657-11662
75. Papassotiropoulos A., Lambert J.C., Wavrant-De Vrièze F., Wollmer M.A., von der Kammer H., Streffer J.R., Maddalena A., Huynh K.D., Wolleb S., Lutjohann D., Schneider B., Thal D.R., Grimaldi L.M., Tsolaki M., Kapaki E., Ravid R., Konietzko U., Hegi T., Pasch T., Jung H., Braak H., Amouyel P., Rogaev E.I., Hardy J., Hock C., and Nitsch R.M. Cholesterol 25-hydroxylase on chromosome 10q is a susceptibility gene for sporadic Alzheimer's disease. Neurodegener. Dis. 2 (2005) 233-241
76. Gelissen I.C., Hochgrebe T., Wilson M.R., Easterbrook-Smith S.B., Jessup W., Dean R.T., and Brown A.J. Apolipoprotein J (clusterin) induces cholesterol export from macrophage-foam cells: a potential anti-atherogenic function?. Biochem. J. 331 (1998) 231-237
77. de Silva H.V., Stuart W.D., Duvic C.R., Wetterau J.R., Ray M.J., Ferguson D.G., Albers H.W., Smith W.R., and Harmony J.A. A 70-kDa apolipoprotein designated ApoJ is a marker for subclasses of human plasma high density lipoproteins. J. Biol. Chem. 265 (1990) 13240-13247
78. May P.C., Lampert-Etchells M., Johnson S.A., Poirier J., Masters J.N., and Finch C.E. Dynamics of gene expression for a hippocampal glycoprotein elevated in Alzheimer's disease and in response to experimental lesions in rat. Neuron 5 (1990) 831-839
79. Tycko B., Feng L., Nguyen L., Francis A., Hays A., Chung W.Y., Tang M.X., Stern Y., Sahota A., Hendrie H., and Mayeux R. Polymorphisms in the human apolipoprotein-J/clusterin gene: ethnic variation and distribution in Alzheimer's disease. Hum. Genet. 98 (1996) 430-436
80. Harold D., Abraham R., Hollingworth P., Sims R., Gerrish A., Hamshere M.L., Pahwa J.S., Moskvina V., Dowzell K., Williams A., Jones N., Thomas C., Stretton A., Morgan A.R., Lovestone S., Powell J., Proitsi P., Lupton M.K., Brayne C., Rubinsztein D.C., Gill M., Lawlor B., Lynch A., Morgan K., Brown K.S., Passmore P.A., Craig D., McGuinness B., Todd S., Holmes C., Mann D., Smith A.D., Love S., Kehoe P.G., Hardy J., Mead S., Fox N., Rossor M., Collinge J., Maier W., Jessen F., Schürmann B., van den Bussche H., Heuser I., Kornhuber J., Wiltfang J., Dichgans M., Frölich L., Hampel H., Hüll M., Rujescu D., Goate A.M., Kauwe J.S., Cruchaga C., Nowotny P., Morris J.C., Mayo K., Sleegers K., Bettens K., Engelborghs S., De Deyn P.P., Van Broeckhoven C., Livingston G., Bass N.J., Gurling H., McQuillin A., Gwilliam R., Deloukas P., Al-Chalabi A., Shaw C.E., Tsolaki M., Singleton A.B., Guerreiro R., Mühleisen T.W., Nöthen M.M., Moebus S., Jöckel K.H., Klopp N., Wichmann H.E., Carrasquillo M.M., Pankratz V.S., Younkin S.G., Holmans P.A., O'Donovan M., Owen M.J., and Williams J. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat. Genet. 41 (2009) 1088-1093
81. Lambert J.C., Heath S., Even G., Campion D., Sleegers K., Hiltunen M., Combarros O., Zelenika D., Bullido M.J., Tavernier B., Letenneur L., Bettens K., Berr C., Pasquier F., Fiévet N., Barberger-Gateau P., Engelborghs S., De Deyn P.P., Mateo I., Franck A., Helisalmi S., Porcellini E., Hanon O., European Alzheimer's disease initiative investigators, de Pancorbo M.M., Lendon C., Dufouil C., Jaillard C., Leveillard T., Alvarez V., Bosco P., Mancuso M., Panza F., Nacmias B., Bossù P., Piccardi P., Annoni G., Seripa D., Galimberti D., Hannequin D., Licastro F., Soininen H., Ritchie K., Blanché H., Dartigues J.F., Tzourio C., Gut I., Van Broeckhoven C., Alpérovitch A., Lathrop M., and Amouyel P. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat. Genet. 41 (2009) 1094-1099
82. Yerbury J.J., Poon S., Meehan S., Thompson B., Kumita J.R., Dobson C.M., and Wilson M.R. The extracellular chaperone clusterin influences amyloid formation and toxicity by interacting with prefibrillar structures. FASEB J. 21 (2007) 2312-2322
83. Matsubara E., Frangione B., and Ghiso J. Characterization of apolipoprotein J-Alzheimer's Aβ interaction. J. Biol. Chem. 270 (1995) 7563-7567
84. Bell R.D., Sagare A.P., Friedman A.E., Bedi G.S., Holtzman D.M., Deane R., and Zlokovic B.V. Transport pathways for clearance of human Alzheimer's amyloid β-peptide and apolipoproteins E and J in the mouse central nervous system. J. Cereb. Blood Flow Metab. 27 (2007) 909-918
85. DeMattos R.B., O'dell M.A., Parsadanian M., Taylor J.W., Harmony J.A.K., Bales K.R., Paul S.M., Aronow B.J., and Holtzman D.M. Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease. Proc. Natl Acad. Sci. USA 99 (2002) 10843-10848
86. Nuutinen T., Suuronen T., Kauppinen A., and Salminen A. Clusterin: a forgotten player in Alzheimer's disease. Brain Res. Rev. 61 (2009) 89-104
87. Kölsch H., Lütjohann D., Ludwig M., Schulte A., Ptok U., Jessen F., von Bergmann K., Rao M.L., Maier W., and Heun R. Polymorphism in the cholesterol 24 S-hydroxylase gene is associated with Alzheimer's disease. Mol. Psychiatry 7 (2002) 899-902
88. Papassotiropoulos A., Streffer J.R., Tsolaki M., Schmid S., Thal D., Nicosia F., Iakovidou V., Maddalena A., Lütjohann D., Ghebremedhin E., Hegi T., Pasch T., Träxler M., Brühl A., Benussi L., Binetti G., Braak H., Nitsch R.M., and Hock C. Increased brain beta-amyloid load, phosphorylated tau, and risk of Alzheimer disease associated with an intronic CYP46 polymorphism. Arch. Neurol. 60 (2003) 29-35
89. Hudry E., Van Dam D., Kulik W., De Deyn P.P., Stet F.S., Ahouansou O., Benraiss A., Delacourte A., Bougnères P., Aubourg P., and Cartier N. Adeno-associated Virus Gene Therapy With Cholesterol 24-Hydroxylase Reduces the Amyloid Pathology Before or After the Onset of Amyloid Plaques in Mouse Models of Alzheimer's Disease. Mol. Ther. 18 (2010) 44-53
90. Fourgeux C., Martine L., Björkhem I., Diczfalusy U., Joffre C., Acar N., Creuzot-Garcher C., Bron A., and Bretillon L. Primary open-angle glaucoma: association with cholesterol 24S-hydroxylase (CYP46A1) gene polymorphism and plasma 24-hydroxycholesterol levels. Invest. Ophthalmol. Vis. Sci. 50 (2009) 5712-5717
91. Greeve I., Hermans-Borgmeyer I., Brellinger C., Kasper D., Gomez-Isla T., Behl C., Levkau B., and Nitsch R.M. The human DIMINUTO/DWARF1 homolog seladin-1 confers resistance to Alzheimer's disease-associated neurodegeneration and oxidative stress. J. Neurosci. 20 (2000) 7345-7352
92. Crameri A., Biondi E., Kuehnle K., Lütjohann D., Thelen K.M., Perga S., Dotti C.G., Nitsch R.M., Ledesma M.D., and Mohajeri M.H. The role of seladin-1/DHCR24 in cholesterol biosynthesis, APP processing and Abeta generation in vivo. EMBO J. 25 (2006) 432-443
93. Lämsä R., Helisalmi S., Hiltunen M., Herukka S.K., Tapiola T., Pirttilä T., Vepsäläinen S., and Soininen H. The association study between DHCR24 polymorphisms and Alzheimer's disease. Am. J. Med. Genet. B Neuropsychiatr. Genet. 144B (2007) 906-910
94. Porcellini E., Calabrese E., Guerini F., Govoni M., Chiappelli M., Tumini E., Morgan K., Chappell S., Kalsheker N., Franceschi M., and Licastro F. The hydroxy-methyl-glutaryl CoA reductase promoter polymorphism is associated with Alzheimer's risk and cognitive deterioration. Neurosci. Lett. 416 (2007) 66-70
95. Rodríguez-Rodríguez E., Mateo I., Infante J., Llorca J., García-Gorostiaga I., Vázquez-Higuera J.L., Sánchez-Juan P., Berciano J., and Combarros O. Interaction between HMGCR and ABCA1 cholesterol-related genes modulates Alzheimer's disease risk. Brain Res. 1280 (2009) 166-171
96. Lendon C.L., Talbot C.J., Craddock N.J., Han S.W., Wragg M., Morris J.C., and Goate A.M. Genetic association studies between dementia of the Alzheimer's type and three receptors for apolipoprotein E in a Caucasian population. Neurosci. Lett. 222 (1997) 187-190
97. Zou F., Gopalraj R.K., Lok J., Zhu H., Ling I.F., Simpson J.F., Tucker H.M., Kelly J.F., Younkin S.G., Dickson D.W., Petersen R.C., Graff-Radford N.R., Bennett D.A., Crook J.E., Younkin S.G., and Estus S. Sex-dependent association of a common low density lipoprotein receptor polymorphism with RNA splicing efficiency in the brain and Alzheimers disease. Hum. Mol. Genet. 17 (2008) 929-935
98. Kim J., Castellano J.M., Jiang H., Basak J.M., Parsadanian M., Pham V., Mason S.M., Paul S.M., and Holtzman D.M. Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance. Neuron 64 (2009) 632-644
99. Zhu H., Taylor J.W., Bennett D.A., Younkin S.G., and Estus S. Lack of association of hepatic lipase polymorphisms with late-onset Alzheimer's disease. Neurobiol. Aging 29 (2008) 793-794
100. Baum L., Chen L., Masliah E., Chan Y.S., Ng H.K., and Pang C.P. Lipoprotein lipase mutations and Alzheimer's disease. Am. J. Med. Genet. 88 (1999) 136-139
101. Kang D.E., Saitoh T., Chen X., Xia Y., Masliah E., Hansen L.A., Thomas R.G., Thal L.J., and Katzman R. Genetic association of the low-density lipoprotein receptor-related protein gene (LRP), an apolipoprotein E receptor, with late-onset Alzheimer's disease. Neurology 49 (1997) 56-61
102. Deane R., Bell R.D., Sagare A., and Zlokovic B.V. Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease. CNS Neurol. Disord. Drug Targets 8 (2009) 16-30
103. Sagare A., Deane R., Bell R.D., Johnson B., Hamm K., Pendu R., Marky A., Lenting P.J., Wu Z., Zarcone T., Goate A., Mayo K., Perlmutter D., Coma M., Zhong Z., and Zlokovic B.V. Clearance of amyloid-beta by circulating lipoprotein receptors. Nat. Med. 13 (2007) 1029-1031
104. Deane R., Sagare A., and Zlokovic B.V. The role of the cell surface LRP and soluble LRP in blood-brain barrier Abeta clearance in Alzheimer's disease. Curr. Pharm. Des. 14 (2008) 1601-1605
105. Waldron E., Heilig C., Schweitzer A., Nadella N., Jaeger S., Martin A.M., Weggen S., Brix K., and Pietrzik C.U. LRP1 modulates APP trafficking along early compartments of the secretory pathway. Neurobiol. Dis. 31 (2008) 188-197
106. Liu Q., Zerbinatti C.V., Zhang J., Hoe H.S., Wang B., Cole S.L., Herz J., Muglia L., and Bu G. Amyloid precursor protein regulates brain apolipoprotein E and cholesterol metabolism through lipoprotein receptor LRP1. Neuron 56 (2007) 66-78
107. Sodeyama N., Yamada M., Itoh Y., Suematsu N., Matsushita M., Otomo E., and Mizusawa H. No association of paraoxonase gene polymorphism with atherosclerosis or Alzheimer's disease. Neurology 53 (1999) 1146-1148
108. Leduc V., Théroux L., Dea D., Robitaille Y., and Poirier J. Involvement of paraoxonase 1 genetic variants in Alzheimer's disease neuropathology. Eur. J. Neurosci. 30 (2009) 1823-1830
109. Brune S., Kölsch H., Ptok U., Majores M., Schulz A., Schlosser R., Rao M.L., Maier W., and Heun R. Polymorphism in the peroxisome proliferator-activated receptor alpha gene influences the risk for Alzheimer's disease. J. Neural Transm. 110 (2003) 1041-1050
110. Chinetti G., Lestavel S., Bocher V., Remaley A.T., Neve B., Torra I.P., Teissier E., Minnich A., Jaye M., Duverger N., Brewer H.B., Fruchart J.C., Clavey V., and Staels B. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat. Med. 7 (2001) 53-58
111. Sauder S., Kölsch H., Lütjohann D., Schulz A., von Bergmann K., Maier W., and Heun R. Influence of peroxisome proliferator-activated receptor gamma gene polymorphism on 24S-hydroxycholesterol levels in Alzheimer's patients. J. Neural Transm. 112 (2005) 1381-1389
112. Koivisto A.M., Helisalmi S., Pihlajamaki J., Hiltunen M., Koivisto K., Moilanen L., Kuusisto J., Helkala E.L., Hanninen T., Kervinen K., Kesaniemi Y.A., Laakso M., and Soininen H. Association analysis of peroxisome proliferator-activated receptor gamma polymorphisms and late onset Alzheimer's disease in the Finnish population. Dement. Geriatr. Cogn. Disord. 22 (2006) 449-453
113. Hamilton G., Proitsi P., Jehu L., Morgan A., Williams J., O'Donovan M.C., Owen M.J., Powell J.F., and Lovestone S. Candidate gene association study of insulin signaling genes and Alzheimer's disease: evidence for SOS2, PCK1, and PPARgamma as susceptibility loci. Am. J. Med. Genet. B Neuropsychiatr. Genet. 144 (2007) 508-516
114. Scacchi R., Pinto A., Gambina G., Rosano A., and Corbo R.M. The peroxisome proliferator-activated receptor gamma (PPAR-gamma2) Pro12Ala polymorphism is associated with higher risk for Alzheimer's disease in octogenarians. Brain Res. 1139 (2007) 1-5
115. Sastre M., Dewachter I., Rossner S., Bogdanovic N., Rosen E., Borghgraef P., Evert B.O., Dumitrescu-Ozimek L., Thal D.R., Landreth G., Walter J., Klockgether T., van Leuven F., and Heneka M.T. Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proc. Natl Acad. Sci. USA 103 (2006) 443-448
116. Camacho I.E., Serneels L., Spittaels K., Merchiers P., Dominguez D., and De Strooper B. Peroxisome-proliferator-activated receptor gamma induces a clearance mechanism for the amyloid-beta peptide. J. Neurosci. 24 (2004) 10908-10917
117. Combs C.K., Johnson D.E., Karlo J.C., Cannady S.B., and Landreth G.E. Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J. Neurosci. 20 (2000) 558-567
118. Landreth G., Jiang Q., Mandrekar S., and Heneka M. PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease. Neurotherapeutics 5 (2008) 481-489
119. Kliewer S.A., Umesono K., Noonan D.J., Heyman R.A., and Evans R.M. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 358 (1992) 771-774
120. Kölsch H., Lütjohann D., Jessen F., Popp J., Hentschel F., Kelemen P., Friedrichs S., Maier W., and Heun R. RXRA gene variations influence Alzheimer's disease risk and cholesterol metabolism. J. Cell. Mol. Med. 13 (2009) 589-598
121. You X., Zhang Y.W., Chen Y., Huang X., Xu R., Cao X., Chen J., Liu Y., Zhang X., and Xu H. Retinoid X receptor-alpha mediates (R )-flurbiprofen's effect on the levels of Alzheimer's beta-amyloid. J. Neurochem. 111 (2009) 142-149
122. Wollmer M.A., Streffer J.R., Tsolaki M., Grimaldi L.M., Lütjohann D., Thal D., von Bergmann K., Nitsch R.M., Hock C., and Papassotiropoulos A. Genetic association of acyl-coenzyme A: cholesterol acyltransferase with cerebrospinal fluid cholesterol levels, brain amyloid load, and risk for Alzheimer's disease. Mol. Psychiatry 8 (2003) 635-638
123. Lamsa R., Helisalmi S., Herukka S.K., Tapiola T., Pirttila T., Vepsalainen S., Hiltunen M., and Soininen H. Study on the association between SOAT1 polymorphisms, Alzheimer's disease risk and the level of CSF biomarkers. Dement. Geriatr. Cogn. Disord. 24 (2007) 146-150
124. Puglielli L., Konopka G., Pack-Chung E., Ingano L.A., Berezovska O., Hyman B.T., Chang T.Y., Tanzi R.E., and Kovacs DM D.M. Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide. Nat. Cell Biol. 3 (2001) 905-912
125. Huttunen H.J., Greco C., and Kovacs D.M. Knockdown of ACAT-1 reduces amyloidogenic processing of APP. FEBS Lett. 581 (2007) 1688-1692
126. Bryleva E.Y., Rogers M.A., Chang C.C., Buen F., Harris B.T., Rousselet E., Seidah N.G., Oddo S., LaFerla F.M., Spencer T.A., Hickey W.F., and Chang TY T.Y. ACAT1 gene ablation increases 24(S)-hydroxycholesterol content in the brain and ameliorates amyloid pathology in mice with AD. Proc. Natl Acad. Sci. USA 107 (2010) 3081-3086
127. Huttunen H.J., Puglielli L., Ellis B.C., MacKenzie Ingano L.A., and Kovacs D.M. Novel N-terminal cleavage of APP precludes Abeta generation in ACAT-defective AC29 cells. J. Mol. Neurosci. 37 (2009) 6-15
128. Rogaeva E., Meng Y., Lee J.H., Gu Y., Kawarai T., Zou F., Katayama T., Baldwin C.T., Cheng R., Hasegawa H., Chen F., Shibata N., Lunetta K.L., Pardossi-Piquard R., Bohm C., Wakutani Y., Cupples L.A., Cuenco K.T., Green R.C., Pinessi L., Rainero I., Sorbi S., Bruni A., Duara R., Friedland R.P., Inzelberg R., Hampe W., Bujo H., Song Y.Q., Andersen O.M., Willnow T.E., Graff-Radford N., Petersen R.C., Dickson D., Der S.D., Fraser P.E., Schmitt-Ulms G., Younkin S., Mayeux R., Farrer L.A., and St George-Hyslop P. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat. Genet. 39 (2007) 168-177
129. Spoelgen R., von Arnim C.A., Thomas A.V., Peltan I.D., Koker M., Deng A., Irizarry M.C., Andersen O.M., Willnow T.E., and Hyman B.T. Interaction of the cytosolic domains of sorLA/LR11 with the amyloid precursor protein (APP) and beta-secretase beta-site APP-cleaving enzyme. J. Neurosci. 26 (2006) 418-428
130. Offe K., Dodson S.E., Shoemaker J.T., Fritz J.J., Gearing M., Levey A.I., and Lah J.J. The lipoprotein receptor LR11 regulates amyloid beta production and amyloid precursor protein traffic in endosomal compartments. J. Neurosci. 26 (2006) 1596-1603
131. Andersen O.M., Schmidt V., Spoelgen R., Gliemann J., Behlke J., Galatis D., McKinstry W.J., Parker M.W., Masters C.L., Hyman B.T., Cappai R., and Willnow T.E. Molecular dissection of the interaction between amyloid precursor protein and its neuronal trafficking receptor SorLA/LR11. Biochemistry 45 (2006) 2618-2628
132. Schmidt V., Sporbert A., Rohe M., Reimer T., Rehm A., Andersen O.M., and Willnow T.E. SorLA/LR11 regulates processing of amyloid precursor protein via interaction with adaptors GGA and PACS-1. J. Biol. Chem. 282 (2007) 32956-32964
133. Dodson S.E., Andersen O.M., Karmali V., Fritz J.J., Cheng D., Peng J., Levey A.I., Willnow T.E., and Lah J.J. Loss of LR11/SORLA enhances early pathology in a mouse model of amyloidosis: evidence for a proximal role in Alzheimer's disease. J. Neurosci. 28 (2008) 12877-12886
134. Scherzer C.R., Offe K., Gearing M., Rees H.D., Fang G., Heilman C.J., Schaller C., Bujo H., Levey A.I., and Lah J.J. Loss of apolipoprotein E receptor LR11 in Alzheimer disease. Arch. Neurol. 61 (2004) 1200-1205
135. Spell C., Kölsch H., Lütjohann D., Kerksiek A., Hentschel F., Damian M., von Bergmann K., Rao M.L., Maier W., and Heun R. SREBP-1a polymorphism influences the risk of Alzheimer's disease in carriers of the ApoE4 Allele. Dement. Geriatr. Cogn. Disord. 18 (2004) 245-249
136. Chen C.L., Liu I.H., Fliesler S.J., Han X., Huang S.S., and Huang J.S. Cholesterol suppresses cellular TGF-beta responsiveness: implications in atherogenesis. J. Cell Sci. 120 (2007) 3509-3521
137. Luedecking E.K., DeKosky S.T., Mehdi H., Ganguli M., and Kamboh M.I. Analysis of genetic polymorphisms in the transforming growth factor-beta1 gene and the risk of Alzheimer's disease. Hum. Genet. 106 (2000) 565-569
138. Wyss-Coray T., Lin C., Yan F., Yu G.Q., Rohde M., McConlogue L., Masliah E., and Mucke L. TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice. Nat. Med. 7 (2001) 612-618
139. Town T., Laouar Y., Pittenger C., Mori T., Szekely C.A., Tan J., Duman R.S., and Flavell R.A. Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. Nat. Med. 14 (2008) 681-687
140. Ruiz J., Kouiavskaia D., Migliorini M., Robinson S., Saenko E.L., Gorlatova N., Li D., Lawrence D., Hyman B.T., Weisgraber K.H., and Strickland D.K. The apoE isoform binding properties of the VLDL receptor reveal marked differences from LRP and the LDL receptor. J. Lipid Res. 46 (2005) 1721-1731
141. Okuizumi K., Onodera O., Namba Y., Ikeda K., Yamamoto T., Seki K., Ueki A., Nanko S., Tanaka H., Takahashi H., Oyanagi K., Mizusawa H., Kanazawa I., and Tsuji S. Genetic association of the very low density lipoprotein (VLDL) receptor gene with sporadic Alzheimer's disease. Nat. Genet. 11 (1995) 207-209
142. Dietschy J.M., and Turley S.D. Cholesterol metabolism in the brain. Curr. Opin. Lipidol. 12 (2001) 105-112
143. Björkhem I., and Meaney S. Brain cholesterol: long secret life behind a barrier. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 806-815
144. Kamboh M.I., Harmony J.A., Sepehrnia B., Nwankwo M., and Ferrell R.E. Genetic studies of human apolipoproteins. XX. Genetic polymorphism of apolipoprotein J and its impact on quantitative lipid traits in normolipidemic subjects. Am. J. Hum. Genet. 49 (1991) 1167-1173
145. Chasman D.I., Paré G., Zee R.Y., Parker A.N., Cook N.R., Buring J.E., Kwiatkowski D.J., Rose L.M., Smith J.D., Williams P.T., Rieder M.J., Rotter J.I., Nickerson D.A., Krauss R.M., Miletich J.P., and Ridker P.M. Genetic loci associated with plasma concentration of low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, apolipoprotein A1, and Apolipoprotein B among 6382 white women in genome-wide analysis with replication. Circ. Cardiovasc. Genet. 1 (2008) 21-30
146. Talmud P.J., Drenos F., Shah S., Shah T., Palmen J., Verzilli C., Gaunt T.R., Pallas J., Lovering R., Li K., Casas J.P., Sofat R., Kumari M., Rodriguez S., Johnson T., Newhouse S.J., Dominiczak A., Samani N.J., Caulfield M., Sever P., Stanton A., Shields D.C., Padmanabhan S., Melander O., Hastie C., Delles C., Ebrahim S., Marmot M.G., Smith G.D., Lawlor D.A., Munroe P.B., Day I.N., Kivimaki M., Whittaker J., Humphries S.E., and Hingorani A.D. ASCOT investigators; NORDIL investigators; BRIGHT consortium, gene-centric association signals for lipids and apolipoproteins identified via the humanCVD BeadChip. Am. J. Hum. Genet. 85 (2009) 628-642
147. Chasman D.I., Paré G., Mora S., Hopewell J.C., Peloso G., Clarke R., Cupples L.A., Hamsten A., Kathiresan S., Mälarstig A., Ordovas J.M., Ripatti S., Parker A.N., Miletich J.P., and Ridker P.M. Forty-three loci associated with plasma lipoprotein size, concentration, and cholesterol content in genome-wide analysis. PLoS Genet. 5 (2009) e1000730
148. Papassotiropoulos A., Wollmer M.A., Tsolaki M., Brunner F., Molyva D., Lütjohann D., Nitsch R.M., and Hock C. A cluster of cholesterol-related genes confers susceptibility for Alzheimer's disease. J. Clin. Psychiatry 66 (2005) 940-947
149. Reiman E.M., Webster J.A., Myers A.J., Hardy J., Dunckley T., Zismann V.L., Joshipura K.D., Pearson J.V., Hu-Lince D., Huentelman M.J., Craig D.W., Coon K.D., Liang W.S., Herbert R.H., Beach T., Rohrer K.C., Zhao A.S., Leung D., Bryden L., Marlowe L., Kaleem M., Mastroeni D., Grover A., Heward C.B., Ravid R., Rogers J., Hutton M.L., Melquist S., Petersen R.C., Alexander G.E., Caselli R.J., Kukull W., Papassotiropoulos A., and Stephan D.A. GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers. Neuron 54 (2007) 713-720
150. Bertram L., Lange C., Mullin K., Parkinson M., Hsiao M., Hogan M.F., Schjeide B.M., Hooli B., Divito J., Ionita I., Jiang H., Laird N., Moscarillo T., Ohlsen K.L., Elliott K., Wang X., Hu-Lince D., Ryder M., Murphy A., Wagner S.L., Blacker D., Becker K.D., and Tanzi R.E. Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE. Am. J. Hum. Genet. 83 (2008) 623-632
151. Li H., Wetten S., Li L., St Jean P.L., Upmanyu R., Surh L., Hosford D., Barnes M.R., Briley J.D., Borrie M., Coletta N., Delisle R., Dhalla D., Ehm M.G., Feldman H.H., Fornazzari L., Gauthier S., Goodgame N., Guzman D., Hammond S., Hollingworth P., Hsiung G.Y., Johnson J., Kelly D.D., Keren R., Kertesz A., King K.S., Lovestone S., Loy-English I., Matthews P.M., Owen M.J., Plumpton M., Pryse-Phillips W., Prinjha R.K., Richardson J.C., Saunders A., Slater A.J., St George-Hyslop P.H., Stinnett S.W., Swartz J.E., Taylor R.L., Wherrett J., Williams J., Yarnall D.P., Gibson R.A., Irizarry M.C., Middleton L.T., and Roses A.D. Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. Arch. Neurol. 65 (2008) 45-53
152. Beecham G.W., Martin E.R., Li Y.J., Slifer M.A., Gilbert J.R., Haines J.L., and Pericak-Vance M.A. Genome-wide association study implicates a chromosome 12 risk locus for late-onset Alzheimer disease. Am. J. Hum. Genet. 84 (2009) 35-43
153. Carrasquillo M.M., Zou F., Pankratz V.S., Wilcox S.L., Ma L., Walker L.P., Younkin S.G., Younkin C.S., Younkin L.H., Bisceglio G.D., Ertekin-Taner N., Crook J.E., Dickson D.W., Petersen R.C., Graff-Radford N.R., and Younkin S.G. Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer's disease. Nat. Genet. 41 (2009) 192-198
154. Poduslo S.E., Huang R., Huang J., and Smith S. Genome screen of late-onset Alzheimer's extended pedigrees identifies TRPC4AP by haplotype analysis. Am. J. Med. Genet. B Neuropsychiatr. Genet. 150B (2009) 50-55